How Rythm is different from Theranos

We understand why small-volume blood testing may raise questions about Theranos.

While both involve collecting smaller amounts of blood, Rythm’s technology, laboratory practices, and approach to testing and validation are fundamentally different.

Rythm uses the FDA-cleared Tasso+ device to collect a capillary blood sample from your upper arm into a blood collection tube.

The device collects the sample, it does not perform the laboratory testing.

Your sample is then sent to Rythm’s CLIA-certified, CAP-accredited clinical laboratory, where a defined panel of biomarkers is analyzed using established laboratory instruments and validated clinical assays.

Rythm’s testing process is intentionally designed around the amount of blood collected and the specific biomarkers that can be reliably measured from that sample.

Theranos was developing proprietary laboratory instruments and claimed its technology could perform a large number of tests from very small volumes of blood.

The technology was not demonstrated to reliably support the broad range of clinical testing claims being made.

Rythm is not developing a proprietary analyzer intended to replace established clinical laboratory instruments.

Instead, our approach combines an FDA-cleared collection device, established laboratory technology, validated assays, a defined biomarker panel, and laboratory quality controls.

We believe you should be able to understand how your blood is collected and where it’s tested.

You can independently review our credentials through the CLIA Laboratory Lookup and CAP Accredited Laboratory Directory.